APA

Correale P., Remondo C., Carbone S. F., Ricci V., Migali C., Martellucci I., Licchetta A., Addeo R., Volterrani L., Gotti G., Rotundo M. S., Tassone P., Sperlongano P., Abbruzzese A., Caraglia M., Tagliaferri P. & Francini G. (20101207). Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. : Cancer biology & therapy.

Chicago

Correale Pierpaolo, Remondo Cinzia, Carbone Salvatore Francesco, Ricci Veronica, Migali Cristina, Martellucci Ignazio, Licchetta Antonella, Addeo Raffaele, Volterrani Luca, Gotti Giuseppe, Rotundo Maria Saveria, Tassone Pierfrancesco, Sperlongano Pasquale, Abbruzzese Alberto, Caraglia Michele, Tagliaferri Pierosandro and Francini Guido. 20101207. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. : Cancer biology & therapy.

Harvard

Correale P., Remondo C., Carbone S. F., Ricci V., Migali C., Martellucci I., Licchetta A., Addeo R., Volterrani L., Gotti G., Rotundo M. S., Tassone P., Sperlongano P., Abbruzzese A., Caraglia M., Tagliaferri P. and Francini G. (20101207). Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. : Cancer biology & therapy.

MLA

Correale Pierpaolo, Remondo Cinzia, Carbone Salvatore Francesco, Ricci Veronica, Migali Cristina, Martellucci Ignazio, Licchetta Antonella, Addeo Raffaele, Volterrani Luca, Gotti Giuseppe, Rotundo Maria Saveria, Tassone Pierfrancesco, Sperlongano Pasquale, Abbruzzese Alberto, Caraglia Michele, Tagliaferri Pierosandro and Francini Guido. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. : Cancer biology & therapy. 20101207.